Welcome to the e-CCO Library!

P477: Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open
Year: 2022
Source: ECCO'22
Authors: Allegretti, J.R.(1);Gecse, K.B.(2);Chiorean, M.V.(3);Argollo, M.(4);Guo, X.(5);Lawendy, N.(5);Su, C.(5);Mundayat, R.(6);Paulissen, J.(6);Salese, L.(5);Irving, P.M.(7);
Created: Friday, 11 February 2022, 3:56 PM
P477: The efficacy of adalimumab for the treatment of Korean patients with ulcerative colitis and predictors of response: Preliminary results
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.H. Choi1*, S.J. Park2, J.P. Im3, H.J. Kim4, K.-M. Lee5, J.W. Kim6, S.-A. Jung7, J. Lee8, S.B. Kang9, S.J. Shin10, E.S. Kim11, Y.S. Kim12, T.O. Kim13, H.-S. Kim14, D.I. Park15, H.K. Kim16, E.S. Kim17, J.Y. Jin18, D. Teng19

Created: Thursday, 21 February 2019, 9:14 AM
P478 Thiopurines’ metabolites levels and drug toxicity: a systematic review and meta-analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P.C. Sousa1, M. Estevinho2, C.C. Dias3, D. Martins1, E. Cancela1, F. Pires1, C. Carvalho1, P. Ministro1, F. Magro2

Created: Thursday, 30 January 2020, 10:12 AM
P478: Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study
Year: 2021
Source: ECCO'21 Virtual
Authors: Olmedo-Martín, R.(1);Martín-Rodríguez, M.D.M.(2);Lorenzo-González, L.(3);Lázaro-Sáez, M.(4);Lopez-Vico, M.(2);Hernández-Martínez, Á.(5);Argüelles-Arias, F.(3);Vázquez-Morón, J.M.(6);
Created: Wednesday, 2 June 2021, 4:12 PM
P478: How often high-dose budesonide is necessary for maintenance treatment of collagenous colitis? Efficacy of azathioprine to maintain budesonide-free clinical remission
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. Fernández-Bañares*1, M. Piqueras2, D. Guagnozzi3, V. Robles4, A. Ruiz-Cerulla5, M. J. Casanova6, J. P. Gisbert6, D. Busquets7, A. Lucendo8, Y. Arguedas9, L. Fernández10

Created: Friday, 22 February 2019, 9:49 AM
P478: Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Van den Berghe*1, B. Verstockt2,3, S. Tops1, M. Ferrante2,3, S. Vermeire2,3, A. Gils1

Created: Friday, 22 February 2019, 9:41 AM
P478: Platelet-related indicators for predicting vedolizumab response in patients with Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jiao, J.(1)*;Liu, W.(1);Wang, B.(1);Cao, H.(1);
Created: Friday, 14 July 2023, 11:05 AM
P478: The current place of probiotics in treatment of pouchitis: systematic review
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lichtenstein L., Avni I., Ben-Bassat O.

Created: Wednesday, 20 February 2019, 10:36 AM
P478: The role of proactive measurement of adalimumab trough levels and antibodies to adalimumab in Greek patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Orfanoudaki, E.(1);Gazouli, M.(2);Theodoraki, E.(1);Foteinogiannopoulou, K.(1);Andreou, N.P.(2);Koutroubakis, I.E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P478: Treatment with ferric maltol associated with improvements in quality of life for IBD patients with iron deficiency anaemia
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Schmidt1,2*, D. Baumgart3, B. Bokemeyer4, C. Büning5, S. Howaldt6, A. Stallmach2, C. Singfield7, G. Tremblay8, T. Jones7

Created: Thursday, 21 February 2019, 9:14 AM
P479 The effect of adalimumab on linear growth in children with Crohn’s disease: a post hoc analysis of the PAILOT randomised control trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Matar1, R. Shamir2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz-Mark2, F. Rinawi2, S. Cohen7, C. Topf-Olivestone8, R. Shaoul9, B. Yerushalmi10, S. Ben-Horin11, A. Assa2

Created: Thursday, 30 January 2020, 10:12 AM
P479: Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. R. Lichtenstein1, G. T. Moore*2,3, A. Soonasra4, C. I. Nduaka4, K. Kwok5, L. Wang6, N. Lawendy4, G. Chan4, C. Su4, E. V. Loftus Jr.7

Created: Friday, 22 February 2019, 9:41 AM
P479: Biological therapies and bio-microbial dynamics in inflammatory bowel diseases
Year: 2021
Source: ECCO'21 Virtual
Authors: Tavakoli, P.(1);Vollmer-Conna, U.(2);Hadzi-Pavlovic, D.(2);Grimm, M.C.(3);Vázquez-Campos, X.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P479: Hepcidin and the risk of malnutrition in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Dudkowiak*, K. Neubauer, E. Poniewierka

Created: Friday, 22 February 2019, 9:49 AM
P479: Quality of care and outcomes in a tertiary hospital inflammatory bowel disease (IBD) centre: Monitoring and treatment algorithms during follow-up
Year: 2018
Source: ECCO '18 Vienna
Authors:

Z. Kurti1*, S. Restellini2,3, L. Gonczi1, W. Afif2, T. Bessissow2, G. Wild2, E. Seidman2, R. Kohen2, A. Bitton2, P.L. Lakatos1,2

Created: Thursday, 21 February 2019, 9:14 AM
P479: Reliability and responsiveness of histologic disease activity indices in Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Solitano, V.(1,2,3)*;Schaeffer, D.F.(4);Hogan, M.(2);Pai, R.K.(5);Zou, G.(2,6);Pai, R.K.(7);Vande Casteele, N.(8);Parker, C.E.(2);Remillard, J.(2);Christensen, B.(9,10);Panaccione, R.(2,11);Sands, B.E.(12);D'Haens, G.(2,13);Feagan, B.G.(1,2,6);Ma, C.(2,11);Jairath, V.(1,2,6);
Created: Friday, 14 July 2023, 11:05 AM
P479: Shifting the shunters in a paediatric inflammatory bowel disease population: thiopurine dose splitting versus allopurinol and thiopurine co-therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Chadokufa S.*1,2, Baycheva M.2, Sawney T.3, Acton N.4, Sider S.1, Shah N.2, Huggett B.4, Dziubak R.2, Kiparrissi F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P479: Trends in medication use and treatment patterns in Chinese patients with Inflammatory Bowel Diseases: A multicenter cohort study from 1999 to 2020
Year: 2022
Source: ECCO'22
Authors: Yao, L.(1);Shao, B.(1);Cao, Q.(1);
Created: Friday, 11 February 2022, 3:56 PM
P480 Efficiency and safety of endoscopic balloon dilatation of ileocolonic anastomotic strictures in patients with Crohn’s disease: A multicentric retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Lukáš1, M. Kolar1, M. Vasatko1, P. Klvana2, V. Leksa3, J. Dyntr4, L. Baca5, B. Pipek5, B. Bahnikova6, S. Summerova7

Created: Thursday, 30 January 2020, 10:12 AM
P480: Assessing primary response to biologic therapy in Inflammatory Bowel Disease - ‘the when and the how?’
Year: 2021
Source: ECCO'21 Virtual
Authors: Moore, A.C.(1);Peake, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM